WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the initiation of a Phase III trial to investigate the potential effect of triple-combination inhaled ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca ...

BREZTRI, already approved in over 80 countries for chronic obstructive pulmonary disease (COPD), may now offer hope to asthma sufferers. “We are excited by the positive results from the KALOS and ...

AstraZeneca’s triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) has met the primary endpoints in two Phase III asthma ...

Please provide your email address to receive an email when new articles are posted on . The single inhaler combined budesonide, glycopyrrolate and formoterol fumarate. The risk for cardiopulmonary ...

Breztri can cost around $400 without insurance. Medicare drug plans may cover inhalers for COPD, including drugs like Breztri, but specific coverage and cost depend on the exact plan. Breztri ...

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of annual sales of $3 billion to $5 billion for the 3-in-1 inhaler. Two phase ...

(RTTNews) - AstraZeneca announced the initiation of THARROS, a Phase III trial to investigate the potential effect of triple-combination inhaled therapy BREZTRI AEROSPHERE on severe cardiopulmonary ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (AZN) will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American ...

Pfizer’s Nurtec and AstraZeneca’s Breztri topped an analysis of the digital and omnichannel marketing strategies of the top pharma brands released Thursday morning. Trinity Life Sciences published its ...

THARROS is the first-ever prospective trial to investigate the potential of an inhaled triple therapy to reduce cardiopulmonary events, a key driver of mortality, in COPD First patients dosed in ...